We Build Hearts

HeartWorks has created a first-of-its-kind clinical platform to treat more patients and create more therapies.

Our Goal

Treating children & adults with CHD using novel stemcell therapies that delay the need for
a heart transplant forever.

HeartWorks has designed a first-of-its-kind platform that brings together physicians, 
scientists, and engineers to find and develop treatments for the most severe forms 
of congenital heart defects (CHD) to further advance research in genetics, stem cell biology, clinical trials, and cell-based manufacturing.

We get treatments out of the lab and into clinical trials to be conducted simultaneously in collaboration with a consortium of world-class medical institutions. Our vision is that our therapies will become a cure so children and adults born with CHD will no longer
have to live with CHD.

Bioengineered Cardiac Tissue

Bioengineered Cardiac Tissue produces contracting heart muscle cells that are genetically identical to the patient’s own body; a “seed” that can be planted in a failing heart to help rebuild the weak muscle.


CardiaCord is an autologous (self) cell-based product derived from the umbilical cord that has been shown in pre-clinical settings to stimulate native heart muscle cells to grow faster and bigger.

The Co-Op at HeartWorks

We are on a mission to create the world’s largest database of CHD patients. This will help us tailor clinical trials to the current CHD population and allow us to connect people with opportunities.

Send A Message

Please let us know what's on your mind. Have a question for us? Ask away.
This field is for validation purposes and should be left unchanged.